Biaxin XL Unlikely To Face Generic Competition In Near-Term Following Preliminary Injunctions
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy says it will seek to amend its ANDA for a 500 mg dose to carve out labeling language that may be protected by an Abbott patent.